Abbott filed a lawsuit in a US federal court alleging that Impax Laboratories' proposed generic version of extended-release dyslipidaemia treatment Simcor (niacin/simvastatin) infringes patents on the drug, Impax reported.
The generic drugmaker noted that the litigation was filed in response to a regulatory application it submitted to the FDA seeking to market a generic version of Abbott's drug. Impax indicated that US sales of extended-release Simcor were around $37 million for the 12 months ended September 30.
Reference Articles
Abbott sues Impax over patents for Simcor cholesterol drug - (Bloomberg)
Impax Laboratories confirms patent challenge relating to Simcor extended-release tablets, 1000/20 mg - (Impax)
Impax Laboratories sued for patent infringement by Abbott relating to Simcor cholesterol-reducing drug - (Proactive Investors)
**published in "First Word"
No comments:
Post a Comment